About HLA class I histocompatibility antigen, alpha chain F
HLA class I histocompatibility antigen, alpha chain F (HLA-F) is a protein
from Homo sapiens identified by UniProt accession
P30511, 346 residues long.
MolForge cross-references it against 0 known binders and
217 disease associations.
Target properties
| Protein name | HLA class I histocompatibility antigen, alpha chain F |
|---|
| UniProt accession | P30511 |
|---|
| Gene | HLA-F |
|---|
| Organism | Homo sapiens |
|---|
| Length | 346 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (217)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.46
- Hodgkins lymphoma, mixed cellularity · score 0.28
- multiple sclerosis · score 0.28
- urate measurement · score 0.27
- Crohn's disease · score 0.26
- lymphocyte count · score 0.23
- neurofibrillary tangles measurement · score 0.23
- parental genotype effect measurement · score 0.18
- birth weight · score 0.18
- lung carcinoma · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30511-F1 | alphafold | PREDICTED | 89.62 | — |
Amino-acid sequence (346 residues)
MAPRSLLLLL SGALALTDTW AGSHSLRYFS TAVSRPGRGE PRYIAVEYVD DTQFLRFDSD AAIPRMEPRE PWVEQEGPQY WEWTTGYAKA NAQTDRVALR NLLRRYNQSE AGSHTLQGMN GCDMGPDGRL LRGYHQHAYD GKDYISLNED LRSWTAADTV AQITQRFYEA EEYAEEFRTY LEGECLELLR RYLENGKETL QRADPPKAHV AHHPISDHEA TLRCWALGFY PAEITLTWQR DGEEQTQDTE LVETRPAGDG TFQKWAAVVV PPGEEQRYTC HVQHEGLPQP LILRWEQSPQ PTIPIVGIVA GLVVLGAVVT GAVVAAVMWR KKSSDRNRGS YSQAAV
Explore HLA class I histocompatibility antigen, alpha chain F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets